Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
William C JacksonMing TangMatthew J SchipperHoward M SandlerZachary S ZumstegJason Alexander EfstathiouWilliam U ShipleyWendy SeiferheldHimanshu R LukkaJean-Paul BaharyAnthony L ZietmanThomas M PisanskyKenneth L ZeitzerWilliam A HallRobert T DessRichard D LovettAlexander G BaloghFelix Y FengDaniel E SprattPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
MFS is also a strong surrogate for OS in men receiving salvage radiation therapy for recurrence after prostatectomy. Caution should be used when inferring survival benefit from effects on BF in biochemically recurrent prostate cancer. Lack of comorbidity data did not allow us to assess whether BF in men with no/minimal comorbidity could serve as a surrogate for OS.